These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 7624492)
21. [Experience with levetiracetam in childhood epilepsy]. Neuwirth M; Saracz J; Hegyi M; Paraicz E; Kollár K; Móser J; Rosdy B; Herczegfalvi A; Fogarasi A Ideggyogy Sz; 2006 May; 59(5-6):179-82. PubMed ID: 16786712 [TBL] [Abstract][Full Text] [Related]
22. Spritam--a new formulation of levetiracetam for epilepsy. Med Lett Drugs Ther; 2016 Jun; 58(1497):78-9. PubMed ID: 27305068 [No Abstract] [Full Text] [Related]
23. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325 [TBL] [Abstract][Full Text] [Related]
24. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Genton P; Van Vleymen B Epileptic Disord; 2000 Jun; 2(2):99-105. PubMed ID: 10954241 [TBL] [Abstract][Full Text] [Related]
25. Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. Lippa CF; Rosso A; Hepler M; Jenssen S; Pillai J; Irwin D Am J Alzheimers Dis Other Demen; 2010 Mar; 25(2):149-54. PubMed ID: 19001351 [TBL] [Abstract][Full Text] [Related]
26. Levetiracetam in pediatrics. Vigevano F J Child Neurol; 2005 Feb; 20(2):87-93. PubMed ID: 15794171 [TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. Blais L; Sheehy O; St-Hilaire JM; Bernier G; Godfroid P; LeLorier JJ Pharmacoeconomics; 2005; 23(5):493-503. PubMed ID: 15896100 [TBL] [Abstract][Full Text] [Related]
28. A case of physical and mental adverse drug reactions associated with levetiracetam in post-stroke epilepsy. Robins A; Patel M; Azim A J Am Geriatr Soc; 2012 Jan; 60(1):159-60. PubMed ID: 22239298 [No Abstract] [Full Text] [Related]
29. Early detection of behavioral side effects of antiepileptic treatment using handheld computers. Frings L; Wagner K; Maiwald T; Carius A; Schinkel A; Lehmann C; Schulze-Bonhage A Epilepsy Behav; 2008 Aug; 13(2):402-6. PubMed ID: 18539084 [TBL] [Abstract][Full Text] [Related]
30. Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study. Krüger S; Sarkar R; Pietsch R; Hasenclever D; Bräunig P Psychopharmacology (Berl); 2008 Jun; 198(2):297-9. PubMed ID: 18369598 [No Abstract] [Full Text] [Related]
31. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. Li S; Cao J; Xiao N; Cai F J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208 [TBL] [Abstract][Full Text] [Related]
32. Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases. Aeby A; Poznanski N; Verheulpen D; Wetzburger C; Van Bogaert P Epilepsia; 2005 Dec; 46(12):1937-42. PubMed ID: 16393159 [TBL] [Abstract][Full Text] [Related]
33. Specific effect of levetiracetam in experimental human pain models. Enggaard TP; Klitgaard NA; Sindrup SH Eur J Pain; 2006 Apr; 10(3):193-8. PubMed ID: 15946871 [TBL] [Abstract][Full Text] [Related]
34. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Dinkelacker V; Dietl T; Widman G; Lengler U; Elger CE Epilepsy Behav; 2003 Oct; 4(5):537-47. PubMed ID: 14527496 [TBL] [Abstract][Full Text] [Related]
35. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. Mecarelli O; Vicenzini E; Pulitano P; Vanacore N; Romolo FS; Di Piero V; Lenzi GL; Accornero N Ann Pharmacother; 2004 Nov; 38(11):1816-22. PubMed ID: 15367726 [TBL] [Abstract][Full Text] [Related]
36. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Ferrendelli JA; French J; Leppik I; Morrell MJ; Herbeuval A; Han J; Magnus L Epilepsy Behav; 2003 Dec; 4(6):702-9. PubMed ID: 14698704 [TBL] [Abstract][Full Text] [Related]
37. Obsessive-compulsive behavior induced by levetiracetam. Fujikawa M; Kishimoto Y; Kakisaka Y; Jin K; Kato K; Iwasaki M; Nakasato N J Child Neurol; 2015 Jun; 30(7):942-4. PubMed ID: 25008911 [TBL] [Abstract][Full Text] [Related]
38. Can High-Dose Levetiracetam Be Safe? A Case Report of Prolonged Accidental High-Dose Levetiracetam Administration and Review of the Literature. Kartal A Clin Neuropharmacol; 2017; 40(5):217-218. PubMed ID: 28682928 [TBL] [Abstract][Full Text] [Related]
39. [Pharmacology and clinical results of levetiracetam (E Keppra(®) Tablets), a new antiepileptic drug]. Ishii Y; Tanaka T Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):95-102. PubMed ID: 21321459 [No Abstract] [Full Text] [Related]
40. Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients. Koo DL; Hwang KJ; Kim D; Kim YJ; Kim JY; Shin W; Kim MR; Joo EY; Lee JM; Hong SB Eur Neurol; 2013; 70(1-2):88-94. PubMed ID: 23839084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]